A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Primary Immune Thrombocytopenia
In brief
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.
Key facts
- Study ID
- NCT05653219
- Run by
- Novartis Pharmaceuticals
- People needed
- 152
- Starts
- 2023-02-02
- Expected to finish
- 2028-04-08
- Last updated by the study team
- 2026-06-16
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Colorado Anschutz — Aurora, Colorado, United States
- NorthShore University Health System — Evanston, Illinois, United States
- Boston Medical Center — Boston, Massachusetts, United States
- UMASS Memorial Medical Center — Worcester, Massachusetts, United States
- Michigan Center of Medical Research — Farmington Hills, Michigan, United States
- St Vincent Frontier Cancer Center — Billings, Montana, United States
- Hematology Oncology Association of Rockland — Nyack, New York, United States
- Montefiore Medical Center — The Bronx, New York, United States
- Novartis Investigative Site — CABA, Argentina
- Novartis Investigative Site — Vienna, Austria
- Novartis Investigative Site — Yvoir, Namur, Belgium
- Novartis Investigative Site — Roeselare, West-Vlaanderen, Belgium
- Novartis Investigative Site — Guangzhou, Guangdong, China
- Novartis Investigative Site — Wuhan, Hubei, China
- Novartis Investigative Site — Binzhou, Shandong, China
- Novartis Investigative Site — Hangzhou, Zhejiang, China
- Novartis Investigative Site — Beijing, China
- Novartis Investigative Site — Jinan, China
- Novartis Investigative Site — Tianjin, China
- Novartis Investigative Site — Brno, Czechia
- Novartis Investigative Site — Prague, Czechia
- Novartis Investigative Site — Prague, Czechia
- Novartis Investigative Site — Blois, France
- Novartis Investigative Site — Le Mans, France
- Yuma Regional Medical Center — Yuma, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.